Among these, riluzole (2-amino-6-trifluoromethoxy benzothiazole) is a neuroprotective drug approved for use in amyotrophic lateral sclerosis (Miller et al., 2002), which appears to act through decreasing glutamate release by stabilizing inactive Na + voltage-gated channels, shifting voltage dependence of the channel in the hyperpolarizing direction (Herbert et al., 1990)
Whether this mechanism mediates long-term benefits of treatment with GLP1R agonists or after bariatric surgery remains to be ascertained
Different intensity, different risks, different results
Notably, with a significant 29% risk reduction when looking at three or more years exposure to GLP-1RA. They added, Our sensitivity analysis supported the finding of risk reduction when looking at users of GLP-1RA. These findings support the possibility of GLP-1RA being an adjunctive therapy to IOP-reducing eye drops in glaucoma management, the authors argue
Everyone needs a personalized plan based on many factors, including goals, medical history, family history, and past diet and exercise attempts